Oncolytics Biotech (ONCY) Income from Continuing Operations (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Income from Continuing Operations of 10829768.08 for Q3 2025, down 55.2% year-over-year from 24173684.79 in Q3 2024, and down 127.29% quarter-over-quarter from 4764745.92 in Q2 2025.
Oncolytics Biotech (ONCY) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Income from Continuing Operations for 17 consecutive years, with 10829768.08 the latest figure, recorded in Q3 2025.
- In Q3 2025, Income from Continuing Operations fell 55.2% year-over-year to 10829768.08; the TTM figure through Sep 2025 stood at 28278482.92 (up 50.6% YoY), while the FY2025 annual figure was 28759000.0, down 25.2% from the prior year.
- Income from Continuing Operations retreated to 10829768.08 in Q3 2025 per ONCY's latest filing, from 4764745.92 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5934278.73 in Q2 2021 and bottomed at 37771285.87 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 8352024.68 across 5 years, with a median of 5166239.11 in 2024.
- On a YoY basis, Income from Continuing Operations climbed as much as 217.99% in 2021 and fell as far as 230.26% in 2021.
- Oncolytics Biotech's Income from Continuing Operations stood at 35635822.99 in 2021, then climbed by 15.98% to 29939607.48 in 2022, then declined by 26.16% to 37771285.87 in 2023, then jumped by 84.89% to 5706033.5 in 2024, then tumbled by 89.8% to 10829768.08 in 2025.
- Business Quant data shows ONCY's Income from Continuing Operations at 10829768.08 in Q3 2025, 4764745.92 in Q2 2025, and 5706033.5 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | -9.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.44 Mn |
| Sep 30, 2025 | -10.83 Mn |
| Jun 30, 2025 | -4.76 Mn |
| Dec 31, 2024 | -5.71 Mn |
| Sep 30, 2024 | -6.98 Mn |
| Jun 30, 2024 | -5.17 Mn |
| Dec 31, 2023 | -37.77 Mn |
| Sep 30, 2023 | -7.32 Mn |
| Jun 30, 2023 | -5.58 Mn |
| Mar 31, 2023 | 4.76 Mn |
| Dec 31, 2022 | -29.94 Mn |
| Sep 30, 2022 | -3.17 Mn |
| Jun 30, 2022 | -3.89 Mn |
| Mar 31, 2022 | 5.39 Mn |
| Dec 31, 2021 | -35.64 Mn |
| Sep 30, 2021 | 3.80 Mn |
| Jun 30, 2021 | 5.93 Mn |
| Mar 31, 2021 | -5.12 Mn |
| Dec 31, 2020 | 27.36 Mn |
| Sep 30, 2020 | -5.12 Mn |